| Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma (NCT05312255) | Roswell Park Cancer Institute | 2022-06-28 |
| Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma (NCT05411497) | Mayo Clinic | 2022-06-20 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma (NCT05288062) | Mayo Clinic | 2022-06-15 |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT04850599) | OHSU Knight Cancer Institute | 2022-06-14 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies (NCT05191472) | Alfred Chung, MD | 2022-05-03 |
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (NCT04956302) | Abdullah Khan | 2021-09-27 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma (NCT04892264) | Mayo Clinic | 2021-06-03 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCT04640779) | Mayo Clinic | 2021-02-08 |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab (NCT04407442) | University of California, San Francisco | 2020-11-30 |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT04508790) | City of Hope Medical Center | 2020-11-24 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (NCT04205409) | University of Washington | 2020-06-05 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy (NCT04409314) | University of California, San Francisco | 2020-04-16 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma (NCT03829020) | Mayo Clinic | 2019-04-17 |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT03701321) | National Cancer Institute (NCI) | 2019-01-25 |
| Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT03763162) | M.D. Anderson Cancer Center | 2019-01-17 |
| Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma (NCT03713294) | Mayo Clinic | 2019-01-14 |
| Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy (NCT03457142) | Roswell Park Cancer Institute | 2018-09-11 |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant (NCT03328936) | Ohio State University Comprehensive Cancer Center | 2018-09-01 |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NCT03506802) | Jonsson Comprehensive Cancer Center | 2018-07-10 |
| Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma (NCT03267888) | Emory University | 2018-05-29 |
| BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma (NCT03502577) | Fred Hutchinson Cancer Center | 2018-05-23 |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT03333746) | Yvonne Efebera | 2018-03-21 |
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT03256045) | University of Washington | 2018-02-08 |
| Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma (NCT03338972) | Fred Hutchinson Cancer Center | 2017-11-29 |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia (NCT02948283) | City of Hope Medical Center | 2017-09-05 |
| Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma (NCT03202628) | Mayo Clinic | 2017-07-24 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820) | Mayo Clinic | 2017-04-04 |
| Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma (NCT02971410) | Wake Forest University Health Sciences | 2017-04-01 |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant (NCT03015792) | Mayo Clinic | 2017-03-10 |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement (NCT02765854) | Emory University | 2016-09-01 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) (NCT04439214) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) (NCT04439240) | National Cancer Institute (NCI) | 2016-05-31 |
| Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02509052) | City of Hope Medical Center | 2015-12-02 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma (NCT02506959) | M.D. Anderson Cancer Center | 2015-09-14 |
| Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02514382) | University of Southern California | 2015-08-21 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (NCT02109224) | National Cancer Institute (NCI) | 2014-09-01 |
| Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02095834) | M.D. Anderson Cancer Center | 2014-04-24 |
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01946152) | M.D. Anderson Cancer Center | 2014-03-05 |
| Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT02086552) | Mayo Clinic | 2014-01-17 |
| SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01955434) | Mayo Clinic | 2013-11-01 |
| S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma (NCT01903811) | SWOG Cancer Research Network | 2013-10-01 |
| Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant (NCT01899326) | Albert Einstein College of Medicine | 2013-09-01 |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01936090) | Mayo Clinic | 2013-08-01 |
| Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01842308) | Mayo Clinic | 2013-06-04 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01646762) | Mayo Clinic | 2012-11-05 |
| Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01689987) | OHSU Knight Cancer Institute | 2012-09-01 |
| Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01533194) | National Cancer Institute (NCI) | 2012-04-01 |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT01372540) | M.D. Anderson Cancer Center | 2012-02-24 |
| Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01605032) | Albert Einstein College of Medicine | 2012-02-01 |
| Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib (NCT01415882) | Mayo Clinic | 2012-01-31 |
| 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01503242) | Fred Hutchinson Cancer Center | 2012-01-09 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357) | City of Hope Medical Center | 2011-01-28 |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma (NCT01330173) | National Cancer Institute (NCI) | 2010-12-01 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (NCT01008462) | Fred Hutchinson Cancer Center | 2010-03-18 |
| AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma (NCT01085214) | National Cancer Institute (NCI) | 2010-03-01 |
| Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant (NCT02353468) | University of Colorado, Denver | 2009-12-01 |
| Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma (NCT00966693) | M.D. Anderson Cancer Center | 2009-08-25 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma (NCT00793572) | Fred Hutchinson Cancer Center | 2008-10-01 |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma (NCT00445692) | Fred Hutchinson Cancer Center | 2007-01-10 |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT00450814) | Mayo Clinic | 2006-11-30 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |
| Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms (NCT00082784) | National Cancer Institute (NCI) | 2004-03-01 |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT00066638) | National Cancer Institute (NCI) | 2003-06-01 |